Index
acoustic settler, 162–163
adaptive immune system, 40–47
humoral response, 41–42, 44–46
antibody effector functions, 44–46
antigens and epitopes, 44
B-cells, 41–42
immunoglobulin/antibodies, 42
humoral response, 41–46
adenovirus-vectored vaccines, 270–281
AdV-based COVID-19 vaccine, 280–281
AdV-based Ebola vaccine, 280
AdV structure and vector design, 276–277
cell line selection, 277
examples of AdV-based vaccines, 279–281
limitations in production of AdV, 277–278
production process of AdV vectors, 277–279
productivity of AdV, 278–279
quantitation methods of AdV vector, 279
veterinary vaccines, 279–280
alternating tangential flow, 155–157
annual cycle for influenza vaccine manufacturing,
227–228
batch cultures to intensified processes, 143–146
capsid, 19
cell attachment/use of microcarriers, 94–95
cell-culture production processes, 8–10
cell lines, 57–78
cell banks, 62
cell-based assays, 70–75
cell line-based assays, 72–74
potency tests, 72–74
control of viral risk in future, 74–75
safety tests, 70–72
new technologies, 71–72
safety tests, 70–71
in vitro and in vivo safety tests, 70–71
technology evolution, 63
viral safety, 63–70
raw materials, 70
viral seeds, 62–63
cell lines/ virus production, 87–95
cell retention devices, 149–163
acoustic settler, 162–163
alternating tangential flow, 155–157
disc centrifuge, 157–159
hydrocyclone, 160–161
inclined settler, 159–160
spin filters, 152–153
tangential flow filtration, 153–155
COVID-19, 293–314
future perspectives, 310–311
regulation of vaccines, 304–307
adenovirus vectored COVID-19 vaccines,
306–307
adenovirus vectored vaccines, 305
protein sub-unit vaccines, 308–310
whole virus vaccines, 307–308
RNA vaccines, 299–304
mRNA vaccine design, 300–301
mRNA vaccine manufacturing, 301–302
stability/efficacy of mRNA vaccines,
302–304
SARS-COV-2, 297–310
biology, 295–296
immunology/vaccine rationale, 296–297
critical factors for virus production at high cell
density, 146–149
cytotoxic T-cells, 47
defining viruses, 17–18
design of vaccine, 35–56
adaptive immune system, 40–47
B-cell response, 41–42
humoral response, 41–46
cytotoxic T-cells, 47
DNA vaccine, 52–53
helper T-cells, 46–47
inactivated virus, 51
innate immune system, 37–40
cells of innate immune system, 38
cytokines and chemokines, 38
pattern recognition receptors, 37–38
live attenuated virus, 51
subunit vaccine, 51–52
T-cell recognition, 46
disc centrifuge, 157–159
disposables, 163–166
DNA vaccine, 52–53
downstream processing, 175–200
harvest and clarification, 179–184
new facility design, 192
polishing, 189
process intensification, 192–194
process understanding/high throughput
process-development, 190–191
purification strategies, 178–189
traditional methods for virus purification,
177–178
viral-based vaccines manufacturing--current
challenges, 176–177
315